Zobrazeno 1 - 10
of 613
pro vyhledávání: ''
Autor:
Tadashi Yoshino, Naoya Nakamura, Misa Sakamoto, Tomoka Ikeda, Yuria Egusa, Yoshito Nishimura, Yasuharu Sato, Azusa Fujita, Misato Doi, Noriko Iwaki, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 417-432 (2022)
Cancer Medicine
Cancer Medicine
Background Most patients with methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) show diffuse large B‐cell lymphoma (DLBCL) or classic Hodgkin lymphoma (CHL) types. Patients with MTX‐LPD often have spontaneous remission after MTX
Autor:
Weili Qi, Chuan Li, Wei Peng, Junlong Dai, Shun Ran, Junyi Shen, Yu Zhang, Shusheng Leng, Tian-Fu Wen, Youwei Wu, Xiaoyun Zhang, Fengwei Gao
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8421-8431 (2021)
Cancer Medicine
Cancer Medicine
Background Antiviral therapy should reduce the recurrence of hepatitis B virus‐related hepatocellular carcinoma (HBV‐related HCC) after surgical resection. However, there is little research on whether various antiviral drugs have different progno
Autor:
Henriette Christgen, Laura Bollmann, Mieke Raap, Rachel Wuerstlein, Bahriye Aktas, Ronald E. Kates, Ulrike Nitz, Ulrich Lehmann, Monika Graeser, Oleg Gluz, Michael Braun, Hans Kreipe, Sherko Kuemmel, Claudia Schumacher, Matthias Christgen, Malte Gronewold, Stephan Bartels, Nadia Harbeck, Eva-Maria Grischke, Christine Eulenburg, Isabel Grote, Kerstin Luedtke-Heckenkamp, Leonie Kandt
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8581-8594 (2021)
Cancer Medicine
Cancer Medicine
Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non
Autor:
Neta Goldschmidt, Moshe E. Gatt, Netanel A. Horowitz, Yael Morgenstern, Boaz Nachmias, Shlomzion Aumann
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8866-8875 (2021)
Cancer Medicine
Cancer Medicine
Purpose Primary mediastinal B‐cell lymphoma (PMBCL) is a rare subtype of diffuse large B‐cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose‐adjusted (DA) EPOCH‐R (rituximab, etoposide
Autor:
Yong-Kil Hong, Jeong Hoon Kim, Seok Gu Kang, Se-Hyuk Kim, Kihwan Hwang, Shin Hyuk Kang, Yu Jung Kim, Jong Hee Chang, Chae-Yong Kim, Junhyung Kim, Byung Se Choi, Tae-Young Jung, Tae Min Kim
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 371-379 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 371-379 (2022)
Background An open‐label single‐arm phase 2 study was conducted to evaluate the role of levetiracetam as a sensitizer of concurrent chemoradiotherapy (CCRT) for patients with newly diagnosed glioblastoma. This study aimed to determine the surviva
Autor:
Shuyang Yao, Funda Meric-Bernstam, Amanda Johnston, Nai Shi, John S. Bomalaski, Kimberly Koenig, Filip Janku, Siqing Fu, Sarina Anne Piha-Paul, John Stewart, Apostolia Maria Tsimberidou
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 340-347 (2022)
Cancer Medicine
Cancer Medicine
Background Arginine depletion interferes with pyrimidine metabolism and DNA damage repair pathways. Preclinical data demonstrated that depletion of arginine by PEGylated arginine deiminase (ADI‐PEG 20) enhanced liposomal doxorubicin (PLD) cytotoxic
Autor:
Sebastiano Carlone, Patrizia Piccioli, Vanessa Cossu, Cecilia Marini, Patrizia Castellani, Enrica Balza, Sonia Carta, Anna Rubartelli, Gianmario Sambuceti
Publikováno v:
Cancer Medicine 11 (2022): 183–193. doi:10.1002/cam4.4371
info:cnr-pdr/source/autori:Balza E.; Carlone S.; Carta S.; Piccioli P.; Cossu V.; Marini C.; Sambuceti G.; Rubartelli A.; Castellani P./titolo:Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models/doi:10.1002%2Fcam4.4371/rivista:Cancer Medicine/anno:2022/pagina_da:183/pagina_a:193/intervallo_pagine:183–193/volume:11
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 183-193 (2022)
info:cnr-pdr/source/autori:Balza E.; Carlone S.; Carta S.; Piccioli P.; Cossu V.; Marini C.; Sambuceti G.; Rubartelli A.; Castellani P./titolo:Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models/doi:10.1002%2Fcam4.4371/rivista:Cancer Medicine/anno:2022/pagina_da:183/pagina_a:193/intervallo_pagine:183–193/volume:11
Cancer Medicine
Cancer Medicine, Vol 11, Iss 1, Pp 183-193 (2022)
Triple negative breast cancers (TNBCs) are very aggressive and have a poor prognosis due to lack of efficacious therapies. The only effective treatment is chemotherapy that however is frequently hindered by the occurrence of drug resistance. We appro
Autor:
Blanca Polo, Maria Joao Costa, Ana Vagos Mata, C. Lopes, João F. Lacerda, Daniela Alves, Eduardo Espada, João Raposo
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
High‐dose methylprednisolone plus rituximab (R‐HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo‐immunotherapy and has proven its utility on the treatment of CLL/SLL compl
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8876-8882 (2021)
Cancer Medicine
Cancer Medicine
Background Rearranged during transfection (RET) is a targetable oncogene. RET fusions have been reported in patients with metastatic colorectal cancer (mCRC). However, RET mutations in mCRC are less studied. Here, we aimed to characterize the clinica
Autor:
Kazuomi Takahashi, Shunichi Taki, Chiaki Koike, Yoshitaka Isobe, Toshinori Matsui, Yuko Nishinaga, Kazuhide Sato, Misae Shimizu, Hirotoshi Yasui
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8808-8819 (2021)
Cancer Medicine
Cancer Medicine
Background Human epidermal growth factor receptor 2 (HER2) is tyrosine kinase receptor that belongs to the ErbB family and is overexpressed on the membrane surface of various cancer cells, including small cell lung cancer (SCLC); however, no HER2 tar